Clinical trial NCT02122380
Conditions: Polycystic Ovary Syndrome
Keywords: Growth Hormone Dipeptidyl Peptidase 4 Polycystic Ovary Syndrome
Sponsor: Vanderbilt University
Start date: 2016-02-01; Completion date: 2019-08-01
Enrollment: 23 participants; Allocation: RANDOMIZED; Intervention model: CROSSOVER

Brief summary:
Adults with abdominal obesity are at high risk for cardiovascular disease and also exhibit diminished growth hormone (GH) secretion; the latter further contributes to the development of visceral adiposity, impaired fibrinolysis and inflammation.Growth hormone releasing hormone (GHRH), the primary stimulus for endogenous GH secretion, is a substrate of dipeptidyl peptidase 4 (DPP4); inhibition of DPP4 with the currently available anti-diabetic therapy, sitagliptin, may therefore increase GH secretion by decreasing the degradation of GHRH. The proposed research will test the hypothesis that chronic sitagliptin therapy will enhance GH secretion and vascular function while improving glucose tolerance in patients with impaired GH secretion who are at risk for the development of diabetes mellitus and cardiovascular disease, specifically obese women with polycystic ovary syndrome.

Detailed description:
Thirty-four obese (BMI ≥ 30 kg/m2) females (18-40 years old) with polycystic ovarian syndrome (PCOS) will participate in this randomized, double-blind, placebo-controlled crossover study. The use of oral contraceptives or metformin will be discontinued at least 30 days prior. In females experiencing monthly cycles, the outpatient visit will take place during the mid-luteal phase of the participant's menstrual cycle and the inpatient visit will take place during the late follicular phase.

Subjects will be randomized to treatment order (sitagliptin 100 mg daily vs placebo) using a block randomization algorithm with a block size of two. The dose of sitagliptin was chosen as it is currently the FDA-recommended dose of sitagliptin for type 2 diabetic patients with unimpaired renal function. Subjects will receive standardized dietary counseling throughout the study; visits will be standardized to the menstrual cycle when possible. Subjects will take each therapy for one month; a minimum one month wash-out will separate study treatments. Side effects and compliance with study medication will be assessed at each visit in the clinical research center (CRC).

Each subject will undergo one outpatient visit and one inpatient visit during each treatment. On each study day, subjects will report fasting to the CRC in the morning having abstained from exercise that morning. On each study day, subjects will receive an intravenous catheter. Subjects will undergo an oral glucose tolerance test (OGTT) during the outpatient study visit. During the inpatient study visit, endothelium-dependent and -independent vasodilation will be assessed using flow-mediated dilation technique with ultrasound. Standardized meals will be provided at lunch and dinner. Body composition will be determined in the afternoon. At 8 PM overnight frequent sampling for venous GH will begin every 10 minutes for 12 hours to determine overnight GH secretion.

Arms: arm 1: Sitagliptin 100 mg by mouth daily for 30 days followed by Placebo daily for 30 days arm 2: Placebo daily for 30 days followed by Sitagliptin 100 mg daily for 30 days
Interventions: intervention 1: Sitagliptin intervention 2: Placebo
Intervention descriptions: intervention 1: Sitagliptin 100 mg by mouth daily for 30 Days intervention 2: 1 placebo pill by mouth per day for 30 days

Protocol documents:
Prot_SAP_000.pdf: 
The Effect of Dipeptidyl Peptidase 4 Inhibition on Growth Hormone 
Secretion in Women with Polycystic Ovarian Syndrome
Protocol Date: 01/19/2017
NCT02122380


1/19/17 
1 
 
 
 
 
 
 
 
 
 
The Effect of Dipeptidyl Peptidase 4 Inhibition on Growth Hormone Secretion in 
Women with Polycystic Ovarian Syndrome 
 
Jessica K. Devin, MD MSCI 
 
 
 
 
 
 
 
 


1/19/17 
2 
 
 
 
 
 
 
 
Table of Contents: 
 
1.0 
Background and Previous Human Studies 
2.0 
Rationale and Specific Aims 
3.0 
Inclusion/Exclusion Criteria 
4.0 
Enrollment/Randomization 
5.0 
Study Procedures 
6.0 
Risks 
7.0 
Reporting of Adverse Events or Unanticipated Problems involving Risk to Participants or 
Others 
8.0 
Study Withdrawal/Discontinuation 
9.0 
Statistical Considerations 
10.0 Privacy/Confidentiality Issues 
11.0 Follow-up and Record Retention 
 
 


1/19/17 
3 
 
1. Background and Previous Human Studies 
 
Obesity poses a significant health burden and is associated with an increased risk of heart 
disease. More than one-third of adults in the United States are considered obese and obesity-related 
conditions-including heart disease, stroke and type 2 diabetes mellitus-remain some of the leading 
causes of morbidity and mortality in this country.  Obesity exacerbates cardio-metabolic risk by 
contributing to inflammation, glucose intolerance, impaired fibrinolysis and hypertension. In particular, 
visceral adiposity is a consistent and strong predictor of cardiovascular disease and insulin resistance 
while subcutaneous adiposity appears to exert a protective effect.(1) 
 
 
Growth hormone (GH) secretion is low in patients with obesity, insulin resistance, 
hyperlipidemia, the elderly, and those infected with HIV.(2) Hypothalamic GH releasing hormone 
(GHRH) is the primary regulator of pulsatile GH secretion from the pituitary gland.(3) Spontaneous 
and stimulated GH secretion is negatively associated with visceral adipose tissue.(4) This is due to a 
decreased response to GHRH stimulation and enhanced GH clearance as well as excessive 
somatostatin tone.(5) Compounds which inhibit hypothalamic somatostatin release improve, but do 
not normalize, GH secretion in response to GHRH. Similarly, drugs which lower free fatty acids 
improve GH secretion.  A functional GH deficiency characterized by reduced pulsatile GH secretion 
appears to exist in obesity, and this is somewhat normalized after significant weight loss.(6)  
 
 
Individuals with hypopituitarism and untreated GH deficiency experience increased 
cardiovascular morbidity and increased prevalence of cardio-metabolic risk factors in particular 
visceral adiposity. Prospective studies in adults with hypopituitarism have demonstrated that GH 
replacement improves cardiac function as well as biochemical markers of cardiovascular and 
metabolic disease including fat distribution and inflammatory cytokines.(7-12) GH deficiency is 
associated with impaired endothelium-dependent vasodilation.  Systemic and intra-arterial GH 
infusion increases forearm blood flow in healthy subjects, which is reversed by infusion of the nitric 
oxide synthase inhibitor, L-N-monomethylarginine (L-NMMA).(13;14) Despite these positive findings, 
exogenous GH therapy is not under physiologic negative feedback by IGF-1, does not restore 
pulsatile secretion, and is limited by the side effect of hyperglycemia.(15)  
 
 
GH releasing hormone (GHRH) is a substrate of dipeptidyl peptidase 4 (DPP4) and thus 
inhibition of DPP4 may influence GH secretion. DPP4 is a ubiquitously expressed cell surface serine 
protease which cleaves a dipeptide containing a penultimate proline or alanine. In vitro DPP4 rapidly 
cleaves human GHRH(1-44)-NH2 to the biologically inactive GHRH (3-44)-NH2.(16;17) Conversion to 
GHRH (3-44)-NH2 is 82% blocked in vitro by diprotin A, a DPP4 competitive inhibitor, or by amino 
acid substitution at either position 1 or 2.(18) In vivo, injection of exogenous GHRH(1-44)-NH2 into 
healthy subjects produces GHRH (3-44)-NH2 within 1 minute, demonstrating a half-life of GHRH (1-
44) of only 6.7 minutes.(19) Others have exploited these findings to develop a DPP4-resistant GHRH 
analogue therapy that increases endogenous pulsatile GH secretion, specifically daily subcutaneous 
Tesamorelin which was approved in 2010 for the reduction of visceral adiposity in HIV-associated 
lipodystrophy.(20) Twelve months of Tesamorelin therapy in 60 obese subjects selectively reduced 
visceral adiposity and improved triglycerides, C-reactive protein and carotid intima-media thickness 
without affecting glucose homeostasis.(21) Two weeks of Tesamorelin given to 13 healthy males 
elicited a non-significant trend toward increased homeostasis model assessment insulin resistance 
index (HOMA-IR).(22) Tesamorelin is associated with a small increase in hemoglobin A1c in patients 
with HIV.(23) This side effect in high risk individuals is a drawback to Tesamorelin.  
 


1/19/17 
4 
 
 
DPP4 inhibitors improve post-prandial hyperglycemia in patients with type 2 diabetes mellitus 
by decreasing the degradation of the incretin hormones, including glucagon like peptide-1 (GLP-
1).(16;17) DPP4 inhibitor therapies, such as sitagliptin, are popular due to their once daily oral dosing, 
tolerability, and low incidence of hypoglycemia. Consistent with the ubiquitous expression of DPP4, 
other off-target effects of DPP4 inhibition are increasingly recognized. DPP4 is widely expressed in 
the cardiovascular system, including endothelial cells.(24) Sitagliptin therapy in patients with type 2 
diabetes or the metabolic syndrome produces an anti-inflammatory effect, lowers post-prandial free 
fatty acids, and decreases platelet aggregation.(25-27) DPP4 inhibitor therapy has the potential to 
restore GH secretion by decreasing the degradation of the GHRH stimulus, while simultaneously 
addressing cardio-metabolic risk through a variety of mechanisms. 
 
 
We are currently evaluating the effect of acute DPP4 inhibition on stimulated GH levels and 
forearm blood flow in 14 healthy adults. Our study biostatistician 
(CY) has thus far been un-blinded to the first 6 subjects (4 females, 
2 males) who have completed this double-blinded, placebo-
controlled, crossover study. On each study day, subjects are 
randomized to sitagliptin (200 mg p.o.) vs. matching placebo and 
receive a thirty minute intravenous infusion of Arginine 30 grams 
which stimulates GH secretion via a GHRH-dependent mechanism. 
GH level was positively associated with forearm blood flow (FBF) 
(rs=0.442; p<0.001) and FBF significantly increased only after mean 
time of peak GH.(left) All 
subjects demonstrated 
sufficient responses to arginine 
(peak GH >3 ng/mL), with 
females demonstrating a 
higher peak GH (mean 17.5 
ng/mL ± SEM 3.5 vs. 13.3 ± 
SEM 7.9 in males; p=NS) as 
has previously been 
reported.(28-30). Our 
preliminary data demonstrates a discrete effect of Drug A vs. 
Drug B on GH secretion which is consistent among 4 females, 
where the two drugs represent blinded sitagliptin vs. 
placebo.(above)  
 
 
Obese females with polycystic ovary syndrome (PCOS) have increased visceral adiposity and 
diminished GH secretion-independent of weight or degree of insulin resistance. Females with PCOS 
exhibit an impaired GH response to stimuli including GHRH and a greater than 50% reduction in 24 
hour mean GH levels secondary to diminished GH pulse amplitude.(31-34) Ten percent of 
reproductive-aged women are affected by PCOS; these women are often obese and typically at 
higher risk for the future development of cardiovascular disease and a ten-times higher risk for the 
onset of type 2 diabetes mellitus.(35) Similar to adults with GH deficiency, young women with PCOS 
demonstrate impaired glucose metabolism with a normal fasting blood glucose, increased visceral fat 
and altered endothelial function.(36)  Management options are limited to lifestyle intervention with 
weight loss or the use of metformin. These therapies can be challenging to implement or poorly 
tolerated. Furthermore, metformin therapy is associated with a modest reduction in visceral adiposity 
and an undesirable loss of protective subcutaneous fat.(37)  
 
 


1/19/17 
5 
 
 
In conclusion, patients with obesity and insulin resistance, including young females with 
PCOS, have impaired pulsatile GH secretion.  Sitagliptin and other DPP4 inhibitor therapies are a 
currently approved and well-tolerated oral medication for patients with type 2 diabetes mellitus.  DPP4 
inhibition has the potential to restore physiologic GH secretion in at-risk populations through a variety 
of mechanisms that affect GHRH-stimulated GH secretion. GH replacement therapy improves 
visceral adiposity and markers of cardiovascular risk; its administration, however, is limited by 
undesirable metabolic effects.  The DPP4-resistant GHRH analog, Tesamorelin, is limited by cost and 
adherence issues given its administration by daily subcutaneous injection, in addition to its lack of a 
beneficial effect on glucose homeostasis. We hypothesize that DPP4 inhibition is able to 
pharmacologically manipulate the GH axis and restore GH secretion in a more physiologic fashion 
while improving glucose homeostasis.  The translational application of currently available DPP4 
inhibitor therapies to patients with impaired GH secretion at high cardio-metabolic risk represents a 
cost-effective, high impact strategy which may rapidly be put into effect to address our nation’s 
obesity epidemic. 
 
 
 
2. Rationale and Specific Aims 
 
Forty percent of women affected by PCOS develop glucose intolerance or diabetes by age 40 
and diabetes in this population is associated with a BMI >30 kg/m2. Women with PCOS are at 
increased risk for the development of impaired fibrinolysis and vascular function as well as 
cardiovascular disease.(36) Overnight and pharmacologically stimulated GH secretion is reduced in 
women with PCOS syndrome. (31;33;34) Flow-mediated vasodilation, and specifically nitric oxide-
mediated vasodilation, is impaired in obese women with PCOS.(38;39) We hypothesize that chronic 
therapy with the DPP4 inhibitor, sitagliptin, will increase mean overnight GH secretion and improve 
endothelium-dependent vasodilation in obese women with PCOS.   
 
 
We will secondarily evaluate the effect of chronic DPP4 inhibition on glucose tolerance, as well 
as glucose-suppressed GH and post-glucose rebound GH release. In healthy individuals, GH 
secretion initially declines to a nadir within 90 minutes of glucose ingestion and then increases above 
basal secretion, peaking 3-5 hours after glucose ingestion.(40-42) This “rebound” increase in GH 
secretion following oral glucose is mediated by GHRH.(2) In obese subjects, the early inhibitory effect 
on GH secretion is lost and the “rebound” response is blunted.(41) DPP4 inhibition lowers post-
prandial blood glucoses and free fatty acids by decreasing degradation of the incretin hormones. Both 
free fatty acids and hyperglycemia negatively regulate GH secretion; DPP4 inhibition may thus 
indirectly enhance GH secretion by decreasing post-prandial hyperglycemia and free fatty 
acids.(2;25) We also hypothesize that chronic DPP4 inhibition will improve glucose tolerance, and 
restore early GH inhibition and “rebound” GH release after glucose ingestion. 
 
3. Inclusion/Exclusion Criteria 
 
Thirty-four obese (BMI ≥ 30 kg/m2) females (18-40 years old) with PCOS will participate in this 
randomized, double-blind, placebo-controlled crossover study. The use of oral contraceptives or 
metformin will be discontinued at least 8 weeks prior.  In females experiencing monthly cycles, the 
timing of the inpatient visit will be standardized and will take place during the early follicular phase. 
 
 
 


1/19/17 
6 
 
Inclusion Criteria 
• Females, age 18-45 years 
• BMI ≥ 25 kg/m2 
• Diagnosis of polycystic ovary syndrome defined by 2003 Rotterdam criteria as meeting 
two out of the three below criteria : 
o Oligomenorrhea (menstrual cycles occurring at intervals >35 days, or only 4-9 
cycles per year) or secondary amenorrhea (no cycle in 3 months if previously 
regular OR no cycle in 9 months if previous oligomenorrhea)  
o clinical or biochemical evidence of hyperandrogenism (hirsutism and/or 
documented upper normal or elevated serum testosterone) 
o documented history of polycystic ovaries on ultrasound examination 
o exclusion of other endocrine disorders must be documented in the medical 
record or obtained at the time of the screening visit (normal TSH, prolactin, 17 
OH progesterone) 
Exclusion Criteria 
• Smoking 
• Type 1 or Type 2 diabetes mellitus, as defined by a fasting glucose of 126 mg/dL or 
greater at the time of screening visit or the use of anti-diabetic medication ( Metformin 
use is allowed, but must be presently at a stable dose and continued at the same dose 
throughout the study) 
• Hypertension, as defined by an untreated seated SBP greater than 150 mmHg and/or 
an untreated DBP greater than 95 mmHg at the time of screening visit or the use of anti-
hypertensive medication (with the exception of spironolactone, which may be 
discontinued 30 days prior to initiation of study drug) 
• History of reported or recorded hypoglycemia (plasma glucose < 70 mg/dL) 
• Pregnancy and/or breast-feeding (negative serum pregnancy test will be confirmed prior 
to the initiation of study medication and at each inpatient study visit.) 
• Surgical menopause, defined as s/p total hysterectomy including bilateral salpingo-
oophorectomy 
• Use of oral contraceptive therapy. The use of these contraceptives must be 
discontinued at least 8 weeks prior to study initiation. 
• Anemia defined as hematocrit <35% at screening visit 
• Cardiovascular or cerebrovascular disease, including history of myocardial infarction, 
history of congestive heart failure, history of stroke, or abnormal ECG at screening visit 
• Pulmonary hypertension 
• Impaired renal function, defined as eGFR <60 mL/min/1.73M2 
• Impaired hepatic function (AST or ALT > 2 X upper limit of normal range) 
• Treatment with an investigational drug in the 1 month preceding the study 
• Regular NSAID use including, but not limited to, naproxen, ibuprofen, and aspirin 
• Allergy to any of the medications used in this protocol 
• Regular work of a night-shift or unusual schedule which may disrupt circadian rhythm. 
• Personal or family history (defined as first-degree relative) of pancreatic cancer 
• Personal history of pancreatitis or known pancreatic lesions 
• Coagulopathy as defined by history 
• Mental conditions rendering the subject unable to understand the nature, scope, and 
possible consequences of the study 


1/19/17 
7 
 
• Inability to comply with the protocol, e.g., uncooperative attitude, inability to return for 
follow-up visits, and unlikelihood of completing the study 
• Any underlying or acute disease requiring regular medication that could possibly pose a 
threat to the subject or make implementation of the protocol or interpretation of the study 
results difficult 
 
4. Enrollment/Randomization 
 
Following their initial screening visit, subjects who qualify for the study will be randomized to 
treatment order (sitagliptin 100 mg daily or placebo) using a block randomization algorithm with a 
block size of two. The dose of sitagliptin was chosen as it is currently the FDA-recommended dose of 
sitagliptin for type 2 diabetic patients with unimpaired renal function. Visits will be standardized to the 
menstrual cycle when possible. Subjects will return to the CRC for a medication-dispensing visit 
which will consist of a pregnancy test and dispensing of double-blinded oral study medication 
(placebo or sitagliptin). They will take their first dose of study medication in the CRC.  Subjects will 
take each therapy for one month; a minimum 8-week wash-out will separate study treatments. Side 
effects and compliance with study medication will be assessed at each visit in the CRC. Prior to 
initiation of the second drug, subjects will return to the CRC for an interim screening visit to update 
their medical history and have a blood count checked. If they still meet criteria for inclusion, they will 
then return to the CRC for a medication-dispensing visit which will again consist of a pregnancy 
test and dispensing of the double-blinded oral study medication.  
 
5. Study Procedures 
Protocol: 
 
 
Each subject will undergo one outpatient visit (day 15 ± 4 days of treatment) and one 
inpatient visit (day 30 ± 4 days of treatment) during each treatment. (above Figure) On each study 
day, subjects will report fasting to the CRC in the morning having had no caffeine or alcohol for 24  
 
hours and having abstained from exercise that morning.  They will have a baseline blood pressure 
and pulse obtained in triplicate.  Height and weight will be obtained. On each study day, subjects will 
receive an intravenous catheter. Subjects will undergo an oral glucose tolerance test (OGTT) during 
the outpatient study visit, which will start one hour after their dose of study drug. During the inpatient 


1/19/17 
8 
 
study visit, baseline venous samples will obtained 1 hour after the last dose of study drug. 
Vasodilation at baseline, during reactive hyperemia, and following nitroglycerin will be assessed, as 
detailed below, using high-resolution vascular ultrasound. Standardized meals will be provided at 
lunch and dinner. Body composition will be determined in the afternoon. At 8 PM overnight frequent 
sampling for venous GH will begin every 10 minutes for 12 hours to determine overnight GH 
secretion. Subjects will also complete a health-related quality-of-life questionnaire specific for women 
with PCOS (PCOSQ)(43;44) at the initiation of the study and at each inpatient visit; they will complete 
a CTSA Health Risk Assessment at the beginning of the study. 
 
Assessments:  
 
OGTT will be performed using 75 grams of glucose solution ingested within 10 minutes.  
Baseline venous blood samples will be obtained immediately prior to ingestion of oral glucose 
solution and 1 hour following ingestion of treatment drug that morning. Venous samples will be 
obtained at the following timepoints post ingestion: 15, 30, 45, 60, 90, 120, 150, 180, 210, 240, and 
270 minutes post-glucose load, given that the late rise in GH occurs three to five hours following 
glucose ingestion.(42)  
 
Flow-mediated Dilation.  Patients will be studied in a quiet, temperature-controlled room (22-
23C).  After 15 min of rest in a supine position, the right brachial artery will be imaged with a high 
ultrasound resolution machine for 1 minute. The artery will be scanned over a longitudinal section 3-5 
cm above the elbow. The focus zone will be set to the depth of the anterior vessel wall. Depth and gain 
settings will be optimized to identify the lumen vessel wall interface. The diameter of the brachial artery 
on the dominant arm will be measured continuously at rest, during reactive hyperemia and after 15 
minutes recovery period. A pneumatic tourniquet will be placed on the arm and will be inflated to a 
pressure 200 mm Hg for 5 minutes. Reactive hyperemia will be induced by sudden cuff deflation. The 
brachial artery will be continuously imaged for about 4 minutes after cuff release. After the recovery 
period, patients will receive 0.4 mg nitroglycerin by mouth (held if SBP<110 mmHg or pulse <60 bpm). 
The brachial artery will then be imaged again for an additional 4 minutes.  Brachial artery diameter will 
be analyzed using continuous edge detection and wall tracking software (Brachial analyzer 5.0, Medical 
Imaging Applications LLC, Iowa city, Iowa). We will determine peak diameter using an automated 
mathematical algorithm, previously published (Black MA. et al. Hypertension.2008;51:203-210). FMD 
will be reported as absolute values at baseline, peak hyperemia, and peak following nitroglycerin. FMD 
will also be expressed as % change from baseline and will also be analyzed using allometric modelling 
(Atkinson G and AM Batterham Vascular Medicine. 2013; 18:354-365). 
  
 
Body composition will be assessed by dual-energy x-ray absorptiometry (DXA) to measure 
body composition with the inclusion of a visceral fat measurement. Abdominal visceral fat negatively 
predicts GH secretion following glucose load. (40) GH replacement decreases abdominal fat in GH 
deficient adults. (46) 
 
Overnight spontaneous GH secretion will be assessed using deconvolution analysis from 
venous samples obtained from an indwelling catheter overnight. AutoDecon, a deconvolution 
algorithm validated for analysis of endogenous GH pulsatility, will be used to assess parameters of 
GH secretion including mean overnight GH secretion, GH half-life, GH peak and nadir, number of GH 
peaks, and GH peak area.(47-49) Intravenous catheter patency will be maintained during sampling by 
infusion of intravenous fluids via infusion pump at 20 mL/hour. 


1/19/17 
9 
 
 
  
 
 
 
6. Risks 
1. Repeated blood sampling from venous catheters may cause bleeding or infection.   
2. Frequent blood draws can cause anemia. 
3. Insertion of catheters may cause bleeding, bruising, or infection.   
4. Stopping metformin or oral contraceptives may increase symptoms of high testosterone, 
including acne, hirsutism, and may make menstrual cycles more irregular.  
5. Stopping spironolactone may increase symptoms of acne and hirsutism, and cause an 
increase in blood pressure and fluid retention.  
 
6. Sitagliptin - Drugs like sitagliptin can cause lowered blood sugar (common) in individuals 
with high blood sugar (diabetes). This can result in dizziness, nausea, shaking, sweating, 
fast heartbeat, vision changes, headache, anxiety, tiredness, or confusion. It can rarely 
cause fainting, seizures, or coma. Other side effects are pancreatitis (damage to the 
pancreas), kidney damage (which can be life threatening), allergic reaction (which can be 
life threatening), rash, and liver damage (which can be life threatening). 
7. Oral Glucose (75 grams) Solution-The oral glucose solution is a commercially available 
liquid containing a certain amount of glucose, 75 grams in this case. This solution will be 
swallowed during the outpatient study visit, after the subject has abstained from eating and 
drinking anything but water for at least 8 hours. Side effects may include nausea, 
sweatiness, light-headedness, short of breath or faint after drinking the glucose solution. 
Symptoms are generally limited to a few hours after the test and resolve with food intake. 
8.   Nitroglycerin - Nitroglycerin may lower blood pressure, increase or decrease heart rate, or 
cause the patient to feel dizzy, faint, lightheaded, weak, hot, nauseated or have a 
headache.  If the blood pressure or pulse is too low, the study physician may not perform 
this part of the study. 
 
7. Reporting of Adverse Events or Unanticipated Problems Involving Risk to Participants or 
Others 
 
 
All adverse events and instances of non-compliance with the protocol, subject withdrawals, 
and subject complaints will be formally summarized and reviewed by the Data and Safety Monitoring 
Board (DSMB) bi-annually. The DSMB will receive these in written format and review the study for 
appropriate and timely subject accrual, adherence to the protocol, and data accuracy and 
completeness. The DSMB will provide the PI (Dr. Devin) with written confirmation of receipt of this bi-


1/19/17 
10 
 
annual summary as well as a recommendation with accompanying rationale for study termination or 
continuation. This written confirmation will be provided to the IRB and include results of the review 
and concerns, if any, regarding subject safety or study drug tolerability. The DSMB will ensure that all 
adverse events reporting to the IRB is in accordance with current policies. The members of the DSMB 
will be available for discussion of any questions regarding protocol adherence, consent issues, or 
adverse events. The DSMB will review final results of the study. 
 
 
The DSMB is comprised of 
 is a clinical 
endocrinologist and translational researcher who has experience with the use of sitagliptin in both the 
clinical and research setting. 
 is a translational researcher who has experience with the 
administration of vasoactive substances.  
 is a clinical endocrinologist who has 
extensive experience in the management of patients with polycystic ovarian syndrome.  
 
will serve as chair of the DSMB. 
 
 
All protocols will be reviewed and approved by the 
 before any subject is 
enrolled.  Dr. Devin, her mentor and her co-investigators will closely oversee the protocol. Any 
serious adverse events or toxicities will be reported to the 
 as per policy (currently no 
later than within 10 working days of the investigator’s knowledge) and will immediately be reviewed 
with the DSMB. Any noncompliance with the IRB-approved protocol that increases risk or affects 
participants’ rights, safety or welfare will be similarly reported to the IRB within 10 working days of the 
investigators’ knowledge and immediately reviewed by the DSMB.  
 
 
Any untoward medical event will be classified as an adverse event, regardless of its causal 
relationship with the study. An adverse event will be classified as serious if it a) results in death, b) if 
life-threatening, c) requires inpatient hospitalization or prolongation of existing hospitalization, d) 
results in persistent or significant disability or incapacity, e) is a congenital anomaly or birth defect. 
Non-serious adverse events will be reported to the IRB at the time of continuing review, as is 
currently IRB policy.  
 
 
Dr. Devin will review enrollment progress, all adverse events, protocol adherence data, and 
data quality entry at a minimum of every two weeks with her mentor. Dr. Devin will review with her 
Mentor each enrolled subject’s chart every two weeks for side effects and tolerability of the 
investigational drug. These findings will be included in the DSMB bi-annual report unless previously 
dictated otherwise. 
 
8. Study Withdrawal/Discontinuation 
 
If at any time during the study, a subject develops any symptoms related to study participation that 
subject will be withdrawn from the study. If, in the opinion of the investigator, a subject is non-
compliant, that subject will be withdrawn from the study. Subjects who are withdrawn will be followed 
until symptoms have resolved. 
  
9. Statistical Considerations 
 
Anticipated Results and Data Analysis Plan 


1/19/17 
11 
 
We anticipate that chronic DPP4 inhibition will increase mean overnight GH secretion, enhance 
endothelium-dependent vasodilation, and normalize post-prandial GH secretion. The primary 
endpoints are mean overnight GH secretion and GH levels measured at various time points during 
oral GTT. Secondary endpoint of FMD will be measured at baseline, during reactive hyperemia, and 
following nitroglycerin.  FMD will also be expressed as % change from baseline and will also be 
analyzed using allometric modelling (Atkinson G and AM Batterham Vascular Medicine. 2013; 
18:354-365). Paired t-tests will be used to analyze the data obtained during placebo with sitagliptin. 
Mixed-effect models will be used to analyze the data, with the fixed effect being sitagliptin vs. placebo 
for endpoints such as mean overnight GH. For the post-glucose load GH secretion assessed after 
each of the two treatment periods (sitagliptin vs. placebo), time as a fixed effect and time by treatment 
interaction will be added into the mixed effect model.  This will capture the time trend and how 
sitagliptin impacts the time trend.  For each endpoint, a pre-specified set of covariates that would 
impact the endpoint will be adjusted in the model. 
 
Sample Size and Power Calculation 
 Prior data indicates that a difference in mean overnight GH of the following is statistically significant 
(p<0.005): mean baseline overnight GH 0.7 ± SEM 0.2 vs mean post-therapy overnight GH 1.2 ± 
SEM 0.3 µg/L in 13 subjects.(22) Conservatively assuming a correlation coefficient of 0.6 for the two 
measures on the same subject, the SD for the within subject difference of GH would be 0.87. 
Assuming sitagliptin will increase GH from 0.7 (placebo) to 1.2 µg/L, a sample size of 26, 30, and 34 
completed subjects would have 80, 85, or 90% power, respectively, to detect this clinically meaningful 
difference.  Sample size was calculated with PS Software using the design for a paired t-test.(54)  
Selecting 85% power and assuming a 10% drop-out based upon previous experience with studies of 
this nature, we will enroll 34 patients.  
 
 
10.    Privacy/Confidentiality Issues 
 
Clinical data, including clinical laboratory, will be entered by a member of the Key Study Personnel in 
a protected source database (RedCap).  A unique identification case number will be used to protect 
the confidentiality of the study participants.  The case numbers and participants' names will be 
included in the protected source database, accessible only by Key Study Personnel, but only case 
numbers will be included in any spreadsheet used for the statistical analysis. 
 
 
11.    Follow-up and Record Retention 
 
The total duration of enrollment will be 2 years, and we anticipate completion of a manuscript within 3 
years of initiation. All records will be retained for 7 years following publication of the data.  After that 
time, records may be archived for an additional 5 years and then shredded. 
 
 
Reference List 


1/19/17 
12 
 
 
 
(1)  Reis JP, Araneta MR, Wingard DL, Macera CA, Lindsay SP, Marshall SJ. Overall obesity and abdominal adiposity 
as predictors of mortality in u.s. White and black adults. Ann Epidemiol 2009 Feb;19(2):134-42. 
 
(2)  Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental 
animals and the human. Endocr Rev 1998 Dec;19(6):717-97. 
 
(3)  Goldenberg N, Barkan A. Factors regulating growth hormone secretion in humans. Endocrinol Metab Clin 
North Am 2007 Mar;36(1):37-55. 
 
(4)  Franco C, Veldhuis JD, Iranmanesh A, Brandberg J, Lonn L, Andersson B, et al. Thigh intermuscular fat is 
inversely associated with spontaneous GH release in post-menopausal women with abdominal obesity. Eur J 
Endocrinol 2006 Aug;155(2):261-8. 
 
(5)  Veldhuis JD, Iranmanesh A, Ho KK, Waters MJ, Johnson ML, Lizarralde G. Dual defects in pulsatile growth 
hormone secretion and clearance subserve the hyposomatotropism of obesity in man. J Clin Endocrinol Metab 
1991 Jan;72(1):51-9. 
 
(6)  Scacchi M, Pincelli AI, Cavagnini F. Growth hormone in obesity. Int J Obes Relat Metab Disord 1999 
Mar;23(3):260-71. 
 
(7)  Pfeifer M, Verhovec R, Zizek B, Prezelj J, Poredos P, Clayton RN. Growth hormone (GH) treatment reverses 
early atherosclerotic changes in GH-deficient adults. J Clin Endocrinol Metab 1999 Feb;84(2):453-7. 
 
(8)  Colao A, Di SC, Pivonello R, Cuocolo A, Spinelli L, Bonaduce D, et al. The cardiovascular risk of adult GH 
deficiency (GHD) improved after GH replacement and worsened in untreated GHD: a 12-month prospective 
study. J Clin Endocrinol Metab 2002 Mar;87(3):1088-93. 
 
(9)  Colao A, Di SC, Rota F, Pivonello R, Savanelli MC, Spiezia S, et al. Short-term effects of growth hormone (GH) 
treatment or deprivation on cardiovascular risk parameters and intima-media thickness at carotid arteries in 
patients with severe GH deficiency. J Clin Endocrinol Metab 2005 Apr;90(4):2056-62. 
 (10)  Weaver JU, Monson JP, Noonan K, John WG, Edwards A, Evans KA, et al. The effect of low dose recombinant 
human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk 
factors in hypopituitary adults. J Clin Endocrinol Metab 1995 Jan;80(1):153-9. 
 (11)  Sesmilo G, Biller BM, Llevadot J, Hayden D, Hanson G, Rifai N, et al. Effects of growth hormone administration 
on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A 
randomized, controlled clinical trial. Ann Intern Med 2000 Jul 18;133(2):111-22. 
 (12)  Smith JC, Evans LM, Wilkinson I, Goodfellow J, Cockcroft JR, Scanlon MF, et al. Effects of GH replacement on 
endothelial function and large-artery stiffness in GH-deficient adults: a randomized, double-blind, placebo-
controlled study. Clin Endocrinol (Oxf) 2002 Apr;56(4):493-501. 
 (13)  Napoli R, Guardasole V, Angelini V, D'Amico F, Zarra E, Matarazzo M, et al. Acute effects of growth hormone 
on vascular function in human subjects. J Clin Endocrinol Metab 2003 Jun;88(6):2817-20. 
 (14)  Li G, Del Rincon JP, Jahn LA, Wu Y, Gaylinn B, Thorner MO, et al. Growth hormone exerts acute vascular 
effects independent of systemic or muscle insulin-like growth factor I. J Clin Endocrinol Metab 2008 
Apr;93(4):1379-85. 


1/19/17 
13 
 
 (15)  Jorgensen JO, Moller L, Krag M, Billestrup N, Christiansen JS. Effects of growth hormone on glucose and fat 
metabolism in human subjects. Endocrinol Metab Clin North Am 2007 Mar;36(1):75-87. 
 (16)  Bongers J, Lambros T, Ahmad M, Heimer EP. Kinetics of dipeptidyl peptidase IV proteolysis of growth 
hormone-releasing factor and analogs. Biochim Biophys Acta 1992 Jul 31;1122(2):147-53. 
 (17)  Zhu L, Tamvakopoulos C, Xie D, Dragovic J, Shen X, Fenyk-Melody JE, et al. The role of dipeptidyl peptidase IV 
in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating 
polypeptide-(1-38). J Biol Chem 2003 Jun 20;278(25):22418-23. 
 (18)  Frohman LA, Downs TR, Heimer EP, Felix AM. Dipeptidylpeptidase IV and trypsin-like enzymatic degradation 
of human growth hormone-releasing hormone in plasma. J Clin Invest 1989 May;83(5):1533-40. 
 (19)  Frohman LA, Downs TR, Williams TC, Heimer EP, Pan YC, Felix AM. Rapid enzymatic degradation of growth 
hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the 
NH2 terminus. J Clin Invest 1986 Oct;78(4):906-13. 
 (20)  Falutz J, Allas S, Mamputu JC, Potvin D, Kotler D, Somero M, et al. Long-term safety and effects of 
tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. 
AIDS 2008 Sep 12;22(14):1719-28. 
 (21)  Makimura H, Feldpausch MN, Rope AM, Hemphill LC, Torriani M, Lee H, et al. Metabolic Effects of a Growth 
Hormone-Releasing Factor in Obese Subjects with Reduced Growth Hormone Secretion: A Randomized 
Controlled Trial. J Clin Endocrinol Metab 2012 Sep 26. 
 (22)  Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK. Effects of a growth hormone-releasing hormone 
analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab 2011 
Jan;96(1):150-8. 
 (23)  Stanley TL, Falutz J, Mamputu JC, Soulban G, Potvin D, Grinspoon SK. Effects of tesamorelin on inflammatory 
markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction. AIDS 2011 
Jun 19;25(10):1281-8. 
 (24)  Drucker DJ. The biology of incretin hormones. Cell Metab 2006 Mar;3(3):153-65. 
 (25)  Makdissi A, Ghanim H, Vora M, Green K, Abuaysheh S, Chaudhuri A, et al. Sitagliptin Exerts an 
Antinflammatory Action. J Clin Endocrinol Metab 2012 Jun 28. 
 (26)  Tremblay AJ, Lamarche B, Deacon CF, Weisnagel SJ, Couture P. Effect of sitagliptin therapy on postprandial 
lipoprotein levels in patients with type 2 diabetes. Diabetes Obes Metab 2011 Apr;13(4):366-73. 
 (27)  Gupta AK, Verma AK, Kailashiya J, Singh SK, Kumar N. Sitagliptin: Anti-platelet effect in diabetes and healthy 
volunteers. Platelets 2012 Sep 5. 
 (28)  Merimee TJ, Fineberg SE, Tyson JE. Fluctuations of human growth hormone secretion during menstrual cycle: 
response to arginine. Metabolism 1969 Jul;18(7):606-8. 
 (29)  Fideleff HL, Frigeri AE, Sobrado PG, Llano MN, Ruibal GF, Boquete HR. Reproducibility and variability of the 
arginine test in normal adults. Comparison between sexes. Medicina (B Aires) 1999;59(3):249-53. 
 (30)  Merimee TJ, Rabinowitz D, Riggs L, Burgess JA, Rimoin DL, McKusick VA. Plasma growth hormone after 
arginine infusion. Clinical experiences. N Engl J Med 1967 Feb 23;276(8):434-9. 


1/19/17 
14 
 
 (31)  de Boer JA, Lambalk CB, Hendriks HH, van AC, van der Veen EA, Schoemaker J. Growth hormone secretion is 
impaired but not related to insulin sensitivity in non-obese patients with polycystic ovary syndrome. Hum 
Reprod 2004 Mar;19(3):504-9. 
 (32)  Morales AJ, Laughlin GA, Butzow T, Maheshwari H, Baumann G, Yen SS. Insulin, somatotropic, and luteinizing 
hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J Clin 
Endocrinol Metab 1996 Aug;81(8):2854-64. 
 (33)  Piaditis GP, Kounadi TG, Rangou DB, Trovas GP, Kaklas NA, Tzonou AJ, et al. Dysfunction of the growth 
hormone/insulin-like growth factor-I axis in women with polycystic ovarian syndrome. Clin Endocrinol (Oxf) 
1995 Jun;42(6):635-40. 
 (34)  Orio F, Jr., Palomba S, Colao A, Russo T, Dentico C, Tauchmanova L, et al. GH release after GHRH plus arginine 
administration in obese and overweight women with polycystic ovary syndrome. J Endocrinol Invest 2003 
Feb;26(2):117-22. 
 (35)  Use of insulin sensitizing agents in the treatment of polycystic ovary syndrome. Fertil Steril 2004 Sep;82 Suppl 
1:S181-S183. 
 (36)  Randeva HS, Tan BK, Weickert MO, Lois K, Nestler JE, Sattar N, et al. Cardiometabolic Aspects of the Polycystic 
Ovary Syndrome. Endocr Rev 2012 Jul 24. 
 (37)  Guido M, Romualdi D, Giuliani M, Suriano R, Tienforti D, Costantini B, et al. Effect of metformin on the growth 
hormone response to growth hormone-releasing hormone in obese women with polycystic ovary syndrome. 
Fertil Steril 2005 Nov;84(5):1470-6. 
 (38)  Sprung VS, Atkinson G, Cuthbertson DJ, Pugh CJ, Aziz N, Green DJ, et al. Endothelial function measured using 
flow-mediated dilation in polycystic ovary syndrome: a meta-analysis of the observational studies. Clin 
Endocrinol (Oxf) 2013 Mar;78(3):438-46. 
 (39)  Meyer C, McGrath BP, Teede HJ. Overweight women with polycystic ovary syndrome have evidence of 
subclinical cardiovascular disease. J Clin Endocrinol Metab 2005 Oct;90(10):5711-6. 
 (40)  Iranmanesh A, Lawson D, Veldhuis JD. Distinct metabolic surrogates predict basal and rebound GH secretion 
after glucose ingestion in men. J Clin Endocrinol Metab 2012 Jun;97(6):2172-9. 
 (41)  Grottoli S, Procopio M, Maccario M, Zini M, Oleandri SE, Tassone F, et al. In obesity, glucose load loses its 
early inhibitory, but maintains its late stimulatory, effect on somatotrope secretion. J Clin Endocrinol Metab 
1997 Jul;82(7):2261-5. 
 (42)  Valcavi R, Zini M, Dieguez C, Portioli I, Scanlon MF. Effect of oral glucose on the late growth hormone rise and 
growth hormone responses to GHRH in normal subjects. Clin Endocrinol (Oxf) 1990 May;32(5):539-43. 
 (43)  Cronin L, Guyatt G, Griffith L, Wong E, Azziz R, Futterweit W, et al. Development of a health-related quality-of-
life questionnaire (PCOSQ) for women with polycystic ovary syndrome (PCOS). J Clin Endocrinol Metab 1998 
Jun;83(6):1976-87. 
 (44)  Guyatt G, Weaver B, Cronin L, Dooley JA, Azziz R. Health-related quality of life in women with polycystic ovary 
syndrome, a self-administered questionnaire, was validated. J Clin Epidemiol 2004 Dec;57(12):1279-87. 
 (45)  Pretorius M, Brown NJ. Endogenous nitric oxide contributes to bradykinin-stimulated glucose uptake but 
attenuates vascular tissue-type plasminogen activator release. J Pharmacol Exp Ther 2010 Jan;332(1):291-7. 


1/19/17 
15 
 
 (46)  Bengtsson BA, Brummer RJ, Eden S, Rosen T, Sjostrom L. Effects of growth hormone on fat mass and fat 
distribution. Acta Paediatr Suppl 1992 Sep;383:62-5. 
 (47)  Johnson ML, Pipes L, Veldhuis PP, Farhy LS, Boyd DG, Evans WS. AutoDecon, a deconvolution algorithm for 
identification and characterization of luteinizing hormone secretory bursts: description and validation using 
synthetic data. Anal Biochem 2008 Oct 1;381(1):8-17. 
 (48)  Johnson ML, Pipes L, Veldhuis PP, Farhy LS, Nass R, Thorner MO, et al. AutoDecon: a robust numerical method 
for the quantification of pulsatile events. Methods Enzymol 2009;454:367-404. 
 (49)  Johnson ML, Veldhuis PP, Grimmichova T, Farhy LS, Evans WS. Validation of a deconvolution procedure 
(AutoDecon) for identification and characterization of fasting insulin secretory bursts. J Diabetes Sci Technol 
2010 Sep;4(5):1205-13. 
 (50)  Devin JK, Pretorius M., Billings F.T.IV, Brown N.J. Abstract 613: Interactive Effect of Ace Inhibition and DPP4 
Inhibition on Substance P-stimulated t-PA Release. Hypertension 2012 Sep;60(3 Supplement):A613. 
 (51)  Pretorius M, van Guilder GP, Guzman RJ, Luther JM, Brown NJ. 17Beta-estradiol increases basal but not 
bradykinin-stimulated release of active t-PA in young postmenopausal women. Hypertension 2008 
Apr;51(4):1190-6. 
 (52)  Pretorius M, Rosenbaum DA, Lefebvre J, Vaughan DE, Brown NJ. Smoking impairs bradykinin-stimulated t-PA 
release. Hypertension 2002 Mar 1;39(3):767-71. 
 (53)  Brown NJ, Gainer JV, Stein CM, Vaughan DE. Bradykinin stimulates tissue plasminogen activator release in 
human vasculature. Hypertension 1999 Jun;33(6):1431-5. 
 (54)  Dupont WD, Plummer WD, Jr. Power and sample size calculations. A review and computer program. Control 
Clin Trials 1990 Apr;11(2):116-28.